Study guide

8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents

Key Takeaways Explain This Topic AI

Unfractionated Heparin (monitored via aPTT or anti-Xa) requires vigilant screening for Heparin-Induced Thrombocytopenia (HIT); suspecting HIT necessitates immediate cessation of all heparin and initiation of a direct thrombin inhibitor (Bivalirudin or Argatroban).

Warfarin target INR varies by indication (2.0–3.0 for AFib/VTE; 2.5–3.5 for mechanical mitral valves), whereas DOACs (Apixaban, Rivaroxaban, Dabigatran) provide targeted factor inhibition without routine lab monitoring but are contraindicated in mechanical heart valves.

Dual Antiplatelet Therapy (DAPT) combines Aspirin with a P2Y12 inhibitor (Clopidogrel, Prasugrel, Ticagrelor); Ticagrelor is a direct reversible agent requiring maintenance Aspirin ≤100 mg/day.

Fibrinolytic therapy (Alteplase, Tenecteplase) degrades fibrin in STEMI within 120 minutes of contact when PCI is unavailable, provided no absolute contraindications (prior ICH, active bleeding, recent ischemic stroke) exist.

Specific reversal agents enable immediate restoration of hemostasis: Protamine for UFH, 4-Factor PCC (Kcentra) and Vitamin K for Warfarin, Idarucizumab (Praxbind) for Dabigatran, and Andexanet alfa for Factor Xa inhibitors.

Last updated: August 2026

Parenteral Anticoagulation & Heparin-Induced Thrombocytopenia

Parenteral anticoagulants interrupt the coagulation cascade to prevent thrombus propagation in Acute Coronary Syndromes (ACS), Venous Thromboembolism (VTE), and percutaneous coronary interventions (PCI). Vigilant laboratory monitoring and rapid detection of adverse immune responses are mandatory nursing responsibilities.

1. Unfractionated Heparin (UFH)

Mechanism of Action: High-molecular-weight mucopolysaccharide that binds to antithrombin III (ATIII). This binding produces a conformational change in ATIII, accelerating its inhibition of Factor IIa (thrombin) and Factor Xa by 1,000-fold.

Laboratory Monitoring: Monitored using activated partial thromboplastin time (aPTT, target 1.5 to 2.5× control, typically 60–80 seconds) or anti-Factor Xa assay (target 0.3 to 0.7 units/mL). Titrated using standardized nurse-driven protocol tables.

ACS Dosing Protocol: Initial IV bolus 60 units/kg (maximum 4,000 units), followed by continuous infusion at 12 units/kg/hr (maximum 1,000 units/hr).

Heparin-Induced Thrombocytopenia (HIT): Immune-mediated Type II HIT occurs in up to 3% of patients exposed to UFH. Pathophysiology: Exposure to heparin induces formation of IgG autoantibodies against the Heparin-Platelet Factor 4 (PF4) complex. The immune complex binds platelet Fcgamma RIIa receptors, triggering intense systemic platelet activation, microvascular thrombosis, and rapid platelet consumption.

Clinical Recognition & 4Ts Score: Suspect HIT if platelet count drops by >50% from baseline or absolute count falls <100,000/μ L, typically developing 5–14 days after heparin initiation (or <24 hours if exposed to heparin within the past 100 days). Calculate the 4Ts Score (Thrombocytopenia, Timing of platelet drop, Thrombosis presence, oTher causes of thrombocytopenia).

Emergency HIT Nursing Protocol:

IMMEDIATELY DISCONTINUE all heparin products (including UFH drips, subcutaneous heparin, LMWH, heparin flushes, and heparin-coated catheters).

DO NOT administer platelet transfusions (transfused platelets act as fuel for the antibody-driven thrombotic fire).

Initiate an alternative non-heparin parenteral Direct Thrombin Inhibitor (DTI) :

Bivalirudin: Direct, reversible DTI. Short half-life (25 minutes), cleared via combination of intravascular proteolysis (80%) and renal elimination (20%). Preferred in PCI and in hepatic impairment; because roughly 20% is renally cleared it requires dose reduction in renal impairment, so argatroban is the better choice in severe AKI.

Argatroban: Synthetic direct DTI. Monitored via aPTT (1.5 to 2.5× baseline). Cleared exclusively by the liver; ideal for patients with severe acute kidney injury.

2. Low Molecular Weight Heparin (LMWH - Enoxaparin / Lovenox)

Mechanism of Action: Depolymerized UFH fragments that selectively inhibit Factor Xa over Factor IIa (3:1 to 4:1 ratio of anti-Xa to anti-IIa activity).

Pharmacokinetics & Dosing: High subcutaneous bioavailability (90%) with predictable pharmacokinetics. Dosing for ACS/VTE: 1 mg/kg subcutaneously Q12H. Renally cleared; if Creatinine Clearance (CrCl < 30 mL/min), adjust dosage to 1 mg/kg once daily.

Monitoring: Routine aPTT monitoring is useless. Anti-Xa monitoring is reserved for severe obesity (BMI > 40 kg/m²), renal impairment, pregnancy, and recurrent thrombosis.

Loading diagram... Coagulation Cascade and Antiplatelet Targets

  • Oral Anticoagulants, Antiplatelets, Fibrinolytics & Specific Reversal Protocols
  • Oral Anticoagulants: Warfarin vs. DOACs

Warfarin (Coumadin):

Mechanism of Action: Synthetic Vitamin K antagonist. Inhibits Vitamin K epoxide reductase complex subunit 1 (VKORC1), blocking hepatic gamma-carboxylation of Vitamin K-dependent clotting factors (Factors II, VII, IX, X) and anticoagulant Proteins C and S.

Monitoring & Target INRs: Monitored using International Normalized Ratio (INR).

Target INR 2.0 to 3.0: Non-valvular Atrial Fibrillation, VTE treatment/prevention, bioprosthetic valve replacement.

Target INR 2.5 to 3.5: Mechanical mitral valve prostheses, mechanical aortic valves with additional risk factors.

Bridging Therapy: Full anticoagulant onset requires 3–5 days due to long half-lives of Factor II (60–72 hours) and Factor X. Parenteral anticoagulation (UFH/LMWH) must overlap with Warfarin for at least 5 days AND until INR is therapeutic for ≥ 24 hours.

Direct Oral Anticoagulants (DOACs):

Direct Factor Xa Inhibitors: Apixaban (Eliquis) , Rivaroxaban (Xarelto) , Edoxaban.

Direct Thrombin Inhibitor: Dabigatran (Pradaxa) .

Clinical Indications & Contraindications: Indicated for stroke prevention in non-valvular AFib and VTE management. Absolute Contraindication: Mechanical prosthetic heart valves and moderate-to-severe mitral stenosis (RE-ALIGN trial demonstrated excess stroke and valve thrombosis with Dabigatran).

Antiplatelet Therapy Strategies

Aspirin (ASA): Irreversibly acetylates platelet cyclooxygenase-1 (COX-1), blocking Thromboxane A2 (TXA₂) synthesis for the 7–10 day lifespan of the platelet. Loading dose: 162 to 325 mg non-enteric coated chewed; maintenance: 81 mg daily.

P2Y₁₂ Receptor Antagonists:

Clopidogrel (Plavix): Irreversible prodrug requiring two-step hepatic CYP2C19 bioactivation. Reduced efficacy in CYP2C19 poor metabolizers or when co-administered with CYP2C19 inhibitors (omeprazole). Loading: 300–600 mg; maintenance: 75 mg daily.

Prasugrel (Effient): Irreversible prodrug; more rapid and potent platelet inhibition than clopidogrel. Contraindicated in patients with prior stroke or TIA (high intracranial bleeding risk).

Ticagrelor (Brilinta): Direct-acting, reversible P2Y₁₂ inhibitor (not a prodrug). Dosed 90 mg BID. Special AACN Mandate: Maintenance Aspirin dose co-administered with Ticagrelor MUST NOT exceed 100 mg daily (81 mg daily standard in US); higher aspirin doses reduce ticagrelor efficacy (PLATO trial). Side effects: dyspnea and ventricular pauses.

Cangrelor (Kengreal): Intravenous reversible P2Y₁₂ inhibitor with immediate onset (2 min) and short half-life (3--6 min) for PCI.

Glycoprotein IIb/IIIa Inhibitors (Eptifibatide / Tirofiban): IV agents blocking final common pathway of platelet aggregation. Used in high-risk PCI. Monitor for acute severe thrombocytopenia within 2–4 hours.

Fibrinolytic (Thrombolytic) Therapy

Agents & Mechanism: Alteplase (tPA) and Tenecteplase (TNK-tPA) . Recombinant tissue plasminogen activators that convert plasminogen to plasmin, degrading fibrin clots.

STEMI Indication: Indicated for acute STEMI within 12 hours of symptom onset when primary PCI cannot be performed within 120 minutes of first medical contact. Door-to-needle target time is <30 minutes. Tenecteplase is administered as a single weight-based IV bolus.

Absolute Contraindications: Any prior intracranial hemorrhage, known structural cerebrovascular lesion, malignant intracranial neoplasm, ischemic stroke within 3 months, active internal bleeding (excluding menses), significant closed-head trauma within 3 months, suspected aortic dissection.

Specific Pharmacologic Reversal Protocols

Primary Anticoagulant Primary Reversal Agent(s) Mechanism of Action Dosage & Clinical Protocol

Unfractionated Heparin (UFH) Protamine Sulfate Basic protein that neutralizes acidic heparin via ionic binding 1 mg protamine neutralizes ~ 100 units UFH. Max rate 50 mg over 10 min (prevents severe hypotension & pulmonary vasoconstriction).

Warfarin (Coumadin) 4-Factor PCC (Kcentra) + IV Vitamin K1 Restores functional Factors II, VII, IX, X and Proteins C/S without volume overload Kcentra 25 to 50 units/kg IV based on INR + Vitamin K1 10 mg slow IV. Reverses INR in <30 minutes.

Dabigatran (Pradaxa) Idarucizumab (Praxbind) Humanized monoclonal antibody fragment (Fab) binding free & bound dabigatran 5 g IV administered as two 2.5 g boluses. Immediate, complete reversal.

Factor Xa Inhibitors (Apixaban / Rivaroxaban) Andexanet Alfa (Andexxa) Recombinant modified human Factor Xa decoy protein that sequesters Xa inhibitors IV bolus followed by a 2-hour continuous IV infusion. Restores endogenous Factor Xa activity.